Cite
HARVARD Citation
Aggarwal, R. et al. (n.d.). 341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer. p. A366. [Online].